



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

| | |
|---------------------------------|---|
| Reagent: | Anti-Human CD26 Monoclonal (1F7) |
| Catalog Number: | 2462 |
| Lot Number: | 94054 |
| Release Category: | D |
| Provided: | 50 µl undiluted ascites. |
| Host: | Balb/c mice (NS-1). |
| Titer: | 1:1600 for cytofluorometry. |
| Special Characteristics: | Recognizes the 110 kD human CD26 molecule in immunoprecipitation (a 43 kD protein is also coprecipitated), Western blots, and indirect immunofluorescence. This antibody recognizes a functionally unique CD26 epitope that differs from those recognized by 5F8 and anti-Tal. Antibody 1F7 in combination with antibody to CD3 stimulates T-cell proliferation and IL-2 production. |
| Recommended Storage: | Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result. |
| Contributor: | Dr. Chikao Morimoto. |
| References: | Morimoto C, Torimoto Y, Levinson G, Rudd CE, Schreiber M, Dang NH, Letvin NL, Schlossman SF. 1F7, a novel cell surface molecular involved in helper function of CD4 cells. <i>J Immunol</i> 143 :3430-3439, 1989. Dang NH, Torimoto Y, Sugita K, Daley JF, Schow P, Prado C, Schlossman SF. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody: analysis of surface expression and human T cell activation. <i>J Immunol</i> 145 :3963-3971, 1990. Morimoto C, Schlossman SF. CD26, a key costimulatory molecule on CD4 memory cells. <i>Immunologist</i> 2 :4-7, 1994. |

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-Human CD26 Monoclonal (1F7) from Dr. Chikao Morimoto." Also include the references cited above in any publications.

A patent application has been filed on this reagent. Requests from commercial organizations should be directed to Dr. Morimoto, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, 44 Binney Street, Boston, MA 02115.

Last Updated

January 16, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.